Zobrazeno 1 - 10
of 95
pro vyhledávání: ''
Autor:
Manying Li, Baili Chen, Gaoshi Zhou, Rui Feng, Yun Qiu, Xiaojun Zhuang, Minhu Chen, Tong Li, Zhirong Zeng, Shenghong Zhang, Yao He, Zhenyi Tian
Publikováno v:
Inflammatory Bowel Diseases. 26:1636-1647
Background Gut microbiota dysbiosis is associated with the occurrence and development of Crohn disease (CD). Currently, infliximab (IFX) is used more and more to treat CD; however, gut microbiota alterations during IFX therapy are variable and someti
Publikováno v:
Inflammatory Bowel Diseases. 26:1619-1625
Background Mucosal healing has been associated with long-term response to therapy for Crohn disease (CD). However, little is known about the significance of terminal ileum (TI) transmural thickness in predicting clinical outcomes. Methods In this ret
Autor:
Sandy H. Fang, Joseph K. Canner, Azah Althumari, Brindusa Truta, Jonathan E. Efron, Bashar Safar, Ira L. Leeds
Publikováno v:
Inflammatory Bowel Diseases. 26:1110-1117
Objectives Early discontinuation of infliximab (IFX) in pregnant women with inflammatory bowel disease (IBD) decreases the intrauterine fetal exposure to the drug but may increase the risk of disease flaring leading to poor pregnancy outcomes. In thi
Autor:
Leonardo Salese, Danielle Bargo, Daniel Quirk, Millie D. Long, David Gruben, Timothy W. Smith, Marco DiBonaventura
Publikováno v:
Inflammatory Bowel Diseases
In this real-world analysis, patients with ulcerative colitis frequently required steroids up to a year after initiating immunosuppressant or biologic therapies, with high ulcerative colitis-related costs. This suggests an ongoing challenge in managi
Autor:
Cilénia Baldaia, Paula Moura dos Santos, Sónia Bernardo, Ana Rita Gonçalves, Carolina Simões, Samuel Raimundo Fernandes, Ana Valente, Rui Tato Marinho, Luís Araújo Correia
Publikováno v:
Inflammatory Bowel Diseases. 26:263-270
BACKGROUND Increasing evidence supports the use of reactive therapeutic drug monitoring (TDM) in Crohn's disease (CD) and ulcerative colitis (UC) following secondary loss of response. It is still unknown if proactive TDM can improve clinical outcomes
Autor:
Aruni Tennakoon, Julia Witt, Laura E. Targownik, Gil Kaplan, Sanjay K. Murthy, Juan Nicolás Peña-Sánchez, Harminder Singh, Ellen Kuenzig, Eric I Benchimol, Stephanie Coward, Jennifer Jones, Charles N. Bernstein, Antonio Aviña Zubieta, Lisa M. Lix, Geoffrey C. Nguyen
Publikováno v:
Inflammatory Bowel Diseases. 25:1718-1728
Background Anti–tumor necrosis factor (anti-TNF) drugs are highly effective in the treatment of moderate-to-severe Crohn’s disease (CD) and ulcerative colitis (UC), but they are very costly. Due to their effectiveness, they could potentially redu
Autor:
Yun Qiu, Yao He, Ting Feng, Jin-Shen He, Shomron Ben-Horin, Baili Chen, Zhirong Zeng, Shenghong Zhang, Minhu Chen, Bella Ungar, Sinan Lin, Ren Mao
Publikováno v:
Inflammatory Bowel Diseases. 25:1813-1821
Background Infliximab levels have been reported to be associated with mucosal healing (MH) in Crohn’s disease (CD). However, whether the association differs between postinduction (week 14) and maintenance (week 30) has seldom been investigated. We
Autor:
Olga Isaakovna Obraztsova, Igor Vladimirovich Obraztsov, Marina V. Shapina, Ming-Hsi Wang, Igor L. Khalif, Katerina Evgenievna Shirokikh
Publikováno v:
Inflammatory Bowel Diseases. 25:524-531
Background and aims Ulcerative colitis (UC) is a form of inflammatory bowel disease, and antibodies against tumor necrosis factor (anti-TNF) are used for treatment. Many patients are refractory or lose response to anti-TNF, and predicting response wo
Publikováno v:
Madsen, K G, Pottegård, A, Hallas, J & Kjeldsen, J 2018, ' Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease-A Cohort Study ', Inflammatory Bowel Diseases, vol. 24, no. 12, pp. 2628–2633 . https://doi.org/10.1093/ibd/izy178
Background: In treatment of inflammatory bowel disease (IBD) with anti-tumor necrosis factor-α agents (anti-TNF-α), obesity has been suspected as a cause of accelerated loss of response (LOR). We sought to determine whether overweight IBD patients
Autor:
Ashwin N. Ananthakrishnan, Hamed Khalili, Talin Haritunians, John J. Garber, Dermot P.B. McGovern, Ramnik J. Xavier, Kristin E. Burke
Publikováno v:
Inflammatory Bowel Diseases. 24:1840-1848
BACKGROUND: Despite a high nonresponse rate, predictors of response to anti–tumor necrosis factor (anti-TNF) therapy in ulcerative colitis (UC) remain limited. We aim to determine clinical and genetic predictors of primary nonresponse (PNR) and dur